PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses precision method for patient selection ...
16 September 2024 - C4X Discovery Holdings Limited (“C4XD”), the immuno-inflammation therapeutics company, today announces the discovery of a genetic response signature that identifies responder and ...
16 September 2024 - C4X Discovery Holdings Limited (“C4XD”), the immuno-inflammation therapeutics company, today announces the discovery of a genetic response signature that identifies responder and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback